Global Vaginitis Therapeutics Market to Reach $5.2 Billion by 2027

News provided by

Nov 01, 2022, 08:00 ET

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Abstract:

Whatâ€™s New for 2022?

Global competitiveness and key competitor percentage market shares

Read the full report: https://www.reportlinker.com/p06033213/?utm_source=PRN

Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Global Vaginitis Therapeutics Market to Reach $5.2 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Vaginitis Therapeutics estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 8% over the analysis period 2020-2027. Anti-Bacterial, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anti-Fungal segment is readjusted to a revised 8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $823.7 Million, While China is Forecast to Grow at 12.2% CAGR

The Vaginitis Therapeutics market in the U.S. is estimated at US$823.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$709.3 Million by the year 2027.

Hormone Segment to Record 8.3% CAGR

In the global Hormone segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$477.8 Million in the year 2020 will reach a projected size of US$800 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 9.8% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -
Bayer AG
Janssen Pharmaceuticals Inc.
Lumavita AG
Lupin Pharmaceuticals Inc.
Merck & Co., Inc.
Mission Pharmacal Company
Novartis AG
Pfizer Inc.
Symbiomix Therapeutics LLC
Teva Pharmaceutical Industries Ltd

Read the full report: https://www.reportlinker.com/p06033213/?utm_source=PRN

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Vaginitis Therapeutics - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Vaginitis Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Vaginitis Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Anti-Bacterial by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Anti-Bacterial by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Anti-Bacterial by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Anti-Fungal by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Anti-Fungal by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Anti-Fungal by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Hormone by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Hormone by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Hormone by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Prescription (Rx) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Prescription (Rx) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Prescription (Rx) by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Over-the-Counter (OTC) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Over-the-Counter (OTC) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Over-the-Counter (OTC)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Vaginitis Therapeutics Market Analysis of
Annual Sales in US$ Million for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 20: USA Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 21: USA Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 22: USA 15-Year Perspective for Vaginitis Therapeutics by
Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 23: USA Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 24: USA Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 25: USA 15-Year Perspective for Vaginitis Therapeutics by
Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

CANADA
Table 26: Canada Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 27: Canada Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 28: Canada 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 29: Canada Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 30: Canada Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 31: Canada 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

JAPAN
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 32: Japan Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 33: Japan Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 34: Japan 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 35: Japan Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 36: Japan Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 37: Japan 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

CHINA
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 38: China Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 39: China Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 40: China 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 41: China Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 42: China Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 43: China 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

EUROPE
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 44: Europe Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 45: Europe Historic Review for Vaginitis Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 46: Europe 15-Year Perspective for Vaginitis Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 47: Europe Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 48: Europe Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 49: Europe 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 50: Europe Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 51: Europe Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 52: Europe 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

FRANCE
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 53: France Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 54: France Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 55: France 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 56: France Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 57: France Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 58: France 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

GERMANY
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 59: Germany Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 60: Germany Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 61: Germany 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 62: Germany Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 63: Germany Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 64: Germany 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2021 & 2027

ITALY
Table 65: Italy Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 66: Italy Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 67: Italy 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 68: Italy Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 69: Italy Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 70: Italy 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

UNITED KINGDOM
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 71: UK Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 72: UK Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 73: UK 15-Year Perspective for Vaginitis Therapeutics by
Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 74: UK Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 75: UK Historic Review for Vaginitis Therapeutics by Type -
Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 76: UK 15-Year Perspective for Vaginitis Therapeutics by
Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

SPAIN
Table 77: Spain Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 78: Spain Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 79: Spain 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 80: Spain Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 81: Spain Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 82: Spain 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

RUSSIA
Table 83: Russia Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 84: Russia Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 85: Russia 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 86: Russia Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 87: Russia Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 88: Russia 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 89: Rest of Europe Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Product - Anti-Bacterial,
Anti-Fungal and Hormone - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 90: Rest of Europe Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 91: Rest of Europe 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 93: Rest of Europe Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 94: Rest of Europe 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2021 & 2027

ASIA-PACIFIC
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 95: Asia-Pacific Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 96: Asia-Pacific Historic Review for Vaginitis
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 97: Asia-Pacific 15-Year Perspective for Vaginitis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Product - Anti-Bacterial,
Anti-Fungal and Hormone - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 99: Asia-Pacific Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 100: Asia-Pacific 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 102: Asia-Pacific Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 103: Asia-Pacific 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2021 & 2027

AUSTRALIA
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Australia for 2022 (E)
Table 104: Australia Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 105: Australia Historic Review for Vaginitis Therapeutics
by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 106: Australia 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 107: Australia Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 108: Australia Historic Review for Vaginitis Therapeutics
by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 109: Australia 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2021 & 2027

INDIA
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in India for 2022 (E)
Table 110: India Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 111: India Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 112: India 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 113: India Recent Past, Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 114: India Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 115: India 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027

SOUTH KOREA
Table 116: South Korea Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Product - Anti-Bacterial,
Anti-Fungal and Hormone - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 117: South Korea Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 118: South Korea 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Table 119: South Korea Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 120: South Korea Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 121: South Korea 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2021 & 2027

REST OF ASIA-PACIFIC
Table 122: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Vaginitis Therapeutics by Product -
Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 123: Rest of Asia-Pacific Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 124: Rest of Asia-Pacific 15-Year Perspective for
Vaginitis Therapeutics by Product - Percentage Breakdown of
Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the
Years 2012, 2021 & 2027

Table 125: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Vaginitis Therapeutics by Type - Prescription (Rx)
and Over-the-Counter (OTC) - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 126: Rest of Asia-Pacific Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 127: Rest of Asia-Pacific 15-Year Perspective for
Vaginitis Therapeutics by Type - Percentage Breakdown of Value
Sales for Prescription (Rx) and Over-the-Counter (OTC) for the
Years 2012, 2021 & 2027

LATIN AMERICA
Vaginitis Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Latin America for 2022 (E)
Table 128: Latin America Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Geographic Region - Argentina,
Brazil, Mexico and Rest of Latin America Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 129: Latin America Historic Review for Vaginitis
Therapeutics by Geographic Region - Argentina, Brazil, Mexico
and Rest of Latin America Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 130: Latin America 15-Year Perspective for Vaginitis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Argentina, Brazil, Mexico and Rest of Latin
America Markets for Years 2012, 2021 & 2027

Table 131: Latin America Recent Past, Current & Future Analysis
for Vaginitis Therapeutics by Product - Anti-Bacterial,
Anti-Fungal and Hormone - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 132: Latin America Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 133: Latin America 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2021 & 2027

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033213/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001